Compare Vanguard Short Term Corporate Bond ETF (VCSH) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Short Term Corporate Bond ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Short Term Corporate Bond ETF trades at $78.09, while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| VCSH | WGS | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $80.20 | $167.51 |
52-Week Low | $78.08 | $34.51 |
Market Cap | — | $2.58B |
Enterprise Value | — | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCSH trades at $78.14, down 0.05% on the day, with a bearish technical outlook from moving averages but neutral oscillators. The ETF offers a competitive yield around 4.5% with a short duration of 2.7 years, focusing on investment-grade corporate bonds. Recent news highlights comparisons to treasury ETFs and institutional stake adjustments.
The outlook is cautious due to tight credit spreads and limited price appreciation potential amid rising rates. Risks include corporate credit exposure and interest rate sensitivity, while the high yield and low duration provide some downside protection. Analyst sentiment is mixed, with some downgrades to hold.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
